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B7x (B7-H4 or B7S1) is a member of the B7 family
that can inhibit T cell function. B7x protein is absent
in most normal human tissues and immune cells, but
it is overexpressed in human cancers and often cor-
relates with negative clinical outcome. The expres-
sion pattern and function of B7x suggest that it may
be a potent immunosuppressive pathway in human
cancers. Here, we determined the crystal structure
of the human B7x immunoglobulin variable (IgV)
domain at 1.59 A˚ resolution and mapped the epi-
topes recognized by monoclonal antibodies. We
developed an in vivo system to screen therapeutic
monoclonal antibodies against B7x and found that
the clone 1H3 significantly inhibited growth of B7x-
expressing tumors in vivo via multiple mechanisms.
Furthermore, the surviving mice given 1H3 treatment
were resistant to tumor rechallenge. Our data sug-
gest that targeting B7x on tumors is a promising
cancer immunotherapy and humanized 1H3 may be
efficacious for immunotherapy of human cancers.
INTRODUCTION
T cell costimulation and coinhibition mediated by the B7 ligand
family and the CD28 receptor family have crucial roles in modu-
lating T cell activation, proliferation, and differentiation into
effector function and memory generation (Greenwald et al.,
2005; Zang and Allison, 2007). The B7-1/B7-2/CD28/CTLA-4
pathway is a well-characterized T cell costimulatory and coinhi-
bitory pathway. A monoclonal antibody (mAb) against CTLA-4
was recently approved for the treatment of metastaticmelanoma
(Hodi et al., 2010; Sharma et al., 2011), and CTLA-4-Ig fusion
protein has been used to treat rheumatoid arthritis and prevent
acute kidney transplant rejection (Fiocco et al., 2008; VincentiCell Ret al., 2011). The past decade has witnessed a new era in the dis-
covery of other B7 and CD28 members and understanding of
their immune regulation, including B7h/ICOS, PD-L1/PD-L2/
PD-1, B7-H3/receptor, B7x/receptor, and HHLA2 (B7y/B7-H5/
B7h7)/TMIGD2 (CD28h) (data not shown; Zhao et al., 2013;
Zhu et al., 2013). mAbs against PD-1 and PD-L1 are currently
in clinical trials with cancer patients (Brahmer et al., 2012; Topa-
lian et al., 2012). Clearly, further studies of the less characterized
B7/CD28 pathways will not only sharpen our understanding of
the immune system but also lead to new therapies for a wide
range of diseases.
B7x (B7-H4 or B7S1), a member of the B7 family, can inhibit
T cell proliferation and cytokine production in vitro (Prasad
et al., 2003; Sica et al., 2003; Zang et al., 2003). Recent studies
reveal that overexpression of B7x on pancreatic cells is sufficient
to abolish CD4 or CD8 T cell-induced diabetes (Lee et al., 2012;
Wei et al., 2011), demonstrating that manipulating the B7x
pathwaycanachieve significant functional consequences in vivo.
In contrast to the expression pattern of B7-1 and B7-2, B7x pro-
tein is mainly detected in nonlymphoid organs (Hofmeyer et al.,
2012; Lee et al., 2012; Tringler et al., 2005; Wei et al., 2011).
One of the most intriguing characteristics of B7x is that it is over-
expressed in numerous human cancers and, in many cases,
correlates with negative clinical outcome (Barach et al., 2011;
Janakiram et al., 2012; Zang and Allison, 2007). A large investiga-
tion of B7 family molecules in human malignancy demonstrated
that prostate cancer patients with tumors that express B7x high-
ly are more likely to have disease spread at the time of surgery
and are at an increased risk of cancer recurrence and cancer-
specific death (Zang et al., 2007). In another study, 103 ovarian
cancer samples tested expressed B7x (Zang et al., 2010). In
contrast to tumor tissues, only scattered B7x-positive cells are
detected in nonneoplastic ovarian tissues (Zang et al., 2010). In
line with these results, others have reported that B7x overex-
pression can be seen in human cancers of the lung (Sun et al.,
2006), breast (Tringler et al., 2005), kidney (Krambeck et al.,
2006), pancreas (Awadallah et al., 2008), esophagus (Chen
et al., 2011), skin (Quandt et al., 2011), and gut (Jiang et al.,eports 9, 1089–1098, November 6, 2014 ª2014 The Authors 1089
Table 1. Data Collection, Phasing, and Refinement Statistics for
SAD
Data Collection Native I3C
Space group P 43212 P 43212
Cell dimensions
a, b, g (A˚) 46.5, 46.5, 115.77 46.47, 46.47, 116.15
a, b, g () 90, 90, 90 90, 90, 90
Wavelength 1.075 1.5402
Resolution (A˚) 43.1–1.59 38.72–1.79
Rsym or Rmerge 8.8 (48.9) 16.1 (179)
I/sI 17.7 (1.6) 13.8 (1.8)
Completeness (%) 90.1 (100.0) 86.4 (89.4)
Redundancy 13.3 (13.5) 18.4 (19.7)
Refinement
Resolution (A˚) 1.59
No. reflections 15,194
Rwork/Rfree 17.4 (23.2)/19.2 (22.6)
No. of atoms
Protein 871
Ligand/ion 61
Water 111
B-factors
Protein 15.0
Ligand/ion 13.8
Water 24.1
Rmsd
Bond lengths (A˚) 0.009
Bond angles () 1.474
One crystal was used for native and one for I3C-derivatized data sets.
Values in parentheses are for the highest-resolution shell.2010). In renal cell carcinoma (Krambeck et al., 2006), patients
with tumors expressing B7x are three times more likely to die
of cancer compared to patients lacking B7x. In esophageal
squamous cell carcinoma, expression levels of B7x on tumor
cells are significantly correlated with distant metastasis, tumor
stage and worse survival and are inversely correlated with den-
sities of CD3 T cells in tumor nest and CD8 T cells in tumor
stroma (Chen et al., 2011).
The overexpression of B7x by so many types of human can-
cers suggests that this pathway may be exploited as an impor-
tant immune-evasion mechanism. Here, we report the first
crystal structure of the human B7x immunoglobulin variable
(IgV) domain and developed a cancer immunotherapy using
mAbs recognizing this domain. Our findings suggest that target-
ing B7x on tumors can be an innovative tumor immunotherapy.
RESULTS
Crystal Structure of the Human B7x IgV Domain
Like other B7 family members, B7x possesses extracellular IgV
and immunoglobulin constant (IgC) domains (Prasad et al.,
2003; Sica et al., 2003; Zang et al., 2003). The IgV domain
has previously been characterized as the receptor-binding1090 Cell Reports 9, 1089–1098, November 6, 2014 ª2014 The Authdomain for B7-1 (Stamper et al., 2001), B7-2 (Schwartz et al.,
2001), PD-L1 (Lin et al., 2008), and PD-L2 (La´za´r-Molna´r
et al., 2008). Therefore, we sought to understand the structure
of the B7x IgV domain (B7x-IgV) to inform future studies of its
interaction with receptors and antibodies. Human and murine
B7x sequences share 90% sequence identity overall and in
their IgV domains. The crystals of human B7x-IgV exhibited
diffraction consistent with the space group P43212 (a =
46.5 A˚, b = 46.5 A˚, c = 115.77 A˚; one molecule per asymmetric
unit) and extended to 1.59 A˚ (Table 1). The final model consists
of residues 35–148, which are organized into a b sandwich
composed of sheets ABED (back-sheet; light blue) and
C0 0C0CFG (front-sheet; light green) (Figure 1A). The sequence
of the human B7x-IgV is predicted to contain a single glycosyl-
ation site at Asn112, and we observed a region of well-defined
electron density near this position consistent with the presence
of corresponding to five sugar residues of a branched glycan
(Figure 1B). Superposition of B7x and PD-L1 IgV domains (Fig-
ure 1C) resulted in a root-mean-square deviation (rmsd) of
1.327 A˚ with differences apparent largely in the loop regions,
demonstrating that the fold is highly conserved between these
two B7 family members.
Interaction of mAbs with the B7x IgV Domain
We recently generated B7x-specific mAbs from B7x/ mice
(Wei et al., 2011). mAbs 1H3 (immunoglobulin G1 [IgG1]) and
12D11 (IgG1) bound human or mouse B7x, but not other B7 fam-
ily members (Figure S1A). We estimated the binding rate con-
stants and derived the corresponding equilibrium dissociation
constants (KD’s) for the interactions of mAbs with recombinant
murine B7x ectodomain, as well as murine and human B7x IgV
through surface plasmon resonance (SPR). In these experi-
ments, purified antibodies were immobilized on the biosensor
surface and recombinant protein samples at various concentra-
tions were injected for 120–240 s followed by dissociation in
running buffer. mAbs 1H3, 12D11, and 15D12 strongly interacted
with all of these proteins, and dissociation constants are summa-
rized in Table 2. Representative sensorgrams are shown in
Figure S1B.
Mapping the Epitopes in the Human B7x IgV Domain
Recognized by 1H3 and 12D11
To define the epitope recognized by 1H3 and 12D11, we
generated a series of B7x point mutants and measured their
effect on binding of 1H3 and 12D11. Both antibodies showed
a similar pattern of binding to B7x except in the case of the
I62A mutant. Mutations at residues E59, I62, K63, E74, K84,
F104, D106, Q107, and S135 resulted in greater than 40%
loss of antibody binding (Figure 1D; Figure S1C), even though
their overall expression was similar to wild-type B7x. These
observations suggest that perturbation of these residues did
not cause global B7x misfolding or instability and that the ef-
fects on antibody binding were the result of impaired/unfavor-
able interactions at the binding interface. Clustering of the
identified residues on the surface of the B7x IgV domain
further suggests that the observed effects on antibody binding
were not due to nonspecific effects on overall structure or sta-
bility of B7x.ors
Figure 1. The Structure of the Human B7x IgV Domain and the Epitopes Recognized by Monoclonal Antibody against B7x
(A) Ribbon representation of the structure of human B7x-IgV (front sheet, light green; back sheet, light purple; disulfide, light yellow) is shown in two orientations.
The strands of the b sandwich are labeled in orange; the side chain of Asn112 (purple) and the N-linked glycan (cyan) are shown in stick-figure representation.
(B) Electron density observed near Asn112 corresponds to an N-linked glycan. Ribbon representation of the structure of human B7x-IgV (gray) is shown. Electron
density map (2Fo Fc), contoured at +2s, and covering the area near and including Asn112 is shown in mesh representation (blue). The five residues of N-linked
glycan are shown in stick representation.
(C) Superposition of B7x and PD-L1. Gray represents the IgV domain of human PD-L1, and Pink represents the IgV domain of human B7x.
(D) Ribbon diagram of the IgV domain of B7x showing the location of residues targeted for mutagenesis. Positions that when mutated resulted in at least 40%
reduction in 1H3 binding are highlighted in red, while the remainder of targeted positions are highlighted in blue.Anti-B7x mAb Therapy in Mouse B7x-Expressing Tumor
Models
Although B7x is overexpressed in many human cancers (Jeon
et al., 2013), it is lost rapidly in vitro culture (Dangaj et al.,
2013). We found that most human and mouse tumor cell lines
were B7x protein negative. To develop a functional screening
system for immunotherapy, we first established tumor cell lines
that stably express cell-surface B7x using a retroviral expres-
sion vector transfection. (Figures S2A and S2B). The B7x
expression level on CT26 cells was comparable to the expres-
sion levels of B7x on human cancer cell lines such as MCF-7,
MDA-MB-468, and SK-BR-3 (Figures S2C–S2E). Mouse colon
carcinoma CT26 and murine and human B7x/CT26 were intra-
venously (i.v.) injected into syngeneic BALB/c mice to induce
experimental lung metastasis. The average number of lung tu-
mor nodules in murine and human B7x/CT26 group was 3.5-
fold higher than that in the CT26 group (Figure S2F). In line with
this result, B7x/CT26-injected mice had a lower survival rate
compared to mice receiving naive CT26 cells (Figure S2G).Cell RThese results demonstrate that B7x overexpression on a mu-
rine tumor cell line, like on human tumors, correlates with worse
outcomes.
We next screened the in vivo therapeutic effect of B7x-spe-
cific mAbs in the B7x/CT26-induced pulmonary metastasis
model. B7x/CT26 cells were i.v. injected into BALB/c mice fol-
lowed by intraperitoneal (i.p.) injection of anti-B7x mAbs. On
day 17, lung tumor nodules were examined. We found that
two mAbs, 1H3 and 12D11, significantly reduced 60% of tu-
mor nodules in lungs (Figure 2A). The 4T1 murine tumor model
is a widely used model in which the cancerous cells spontane-
ously metastasize to the lung (Aslakson and Miller, 1992). We
then decided to validate the efficacy of 1H3 in the murine
B7x/4T1 primary tumor model (Figure S2H). 1H3 treatment
significantly suppressed primary tumor growth and efficiently
reduced primary tumor-induced metastatic tumor nodules in
the lung (Figures 2B and S4B). These results from two tumor
models suggest that anti-B7x markedly reduces tumor nodules
in lungs.eports 9, 1089–1098, November 6, 2014 ª2014 The Authors 1091
Table 2. Surface Plasmon Resonance Measurements
mAb kon (M
1$s1) koff (s
1) KD (nM)
Murine B7x (IgV Domain)
1H3 2.455(4) 3 106 0.001248(7) 0.508(3)
12D11 2.140(4) 3 106 0.001341(8) 0.627(4)
15D12 1.790(3) 3 106 0.001135(7) 0.634(4)
Murine B7x
1H3 6.71(3) 3 105 0.001298(7) 1.94(1)
12D11 6.62(4) 3 105 0.001177(7) 1.78(1)
15D12 4.40(3) 3 105 0.001095(6) 2.49(2)
Human B7x (IgV Domain)
1H3 2.53(2) 3 105 0.00917(4) 36.2(3)
12D11 2.13(1) 3 105 0.00928(3) 43.5(3)
15D12 1.388(7) 3 105 0.01039(2) 74.9(4)
The value in parentheses denotes the SE in the last digit.Anti-B7x mAb Therapy in a Human B7x-Expressing
Tumor Model
B7x is very evolutionally conserved (Prasad et al., 2003; Sica
et al., 2003; Zang et al., 2003), and mature B7x protein shares
90% amino acid identity in the extracellular domains between
human and mice. Since both 1H3 and 12D11 recognized human
B7x (Table 2), we wanted to test the therapeutic effects of these
two mAbs in a human B7x-expressing tumor model in vivo. Like
mouse B7x, the expression of human B7x on CT26 markedly
increased tumor nodules in the lung (Figure S2F). We then
examined the effect of mAbs on hB7x/CT26 in vivo. Mice were
i.v. injected with hB7x/CT26 and then treated with 1H3 or
12D11. On day 17, the average numbers of lung tumor nodules
in 1H3-treated and 12D11-treated groups were 97 and 236,
respectively, whereas the number in the control group was
251 (Figure 2C). Because proteins in the tumor microenviron-
ments can be modified by posttranslational modifications such
as glycosylation and phosphorylation, we questioned whether
1H3 recognized human B7x that is naturally expressed in human
tumors. Using immunohistochemical staining, we found that
1H3 recognized nature B7x in various human cancers from the
colon, ovary, skin, lung, breast, liver, nasal cavity, liposarcoma,
pancreas, and stomach (Figure 2D). These results suggest that
human B7x promotes tumor growth in vivo and that mAb 1H3
recognizes human B7x and inhibits progression of these tumors
in vivo. As 1H3 was the only mAb that inhibited both human and
mouse B7x-mediated tumor progression, we used it for the sub-
sequent experiments.
1H3 mAb-Treated Mice Survive Tumor Rechallenge
We next investigated the effect of 1H3 on the survival of mice
bearing B7x/CT26 tumor. In agreement with the lung tumor
nodule results, 1H3-treated mice had a significant lower mortal-
ity than did control immunoglobulin G (IgG)-treated mice. By day
60 postinjection of tumor, 100% of IgG-treated mice were dead,
whereas only 50% of 1H3-treated mice had died (Figure 3A).
These surviving mice appeared to be healthy. We then examined
whether the surviving mice had resistance to the tumor rechal-
lenge. These mice were rechallenged with the same number of1092 Cell Reports 9, 1089–1098, November 6, 2014 ª2014 The AuthB7x/CT26 cells, and all of them remained alive. On day 120,
mice were sacrificed and their lungs were free of visible tumor
nodules. Furthermore, hematoxylin and eosin (H&E) staining of
lung sections from these mice showed that they were free of
cancerous cells (Figure 3B).
Anti-B7x Therapy Increases Infiltrating T and NK Cells
and Decreases Infiltrating MDSCs in Tumors
To dissect the therapeutic mechanisms of 1H3 treatment, we
prepared single-cell suspensions from tumor-bearing lungs
and analyzed the immune cells by flow cytometry. 1H3-treated
mice had a significantly higher percentage of CD45+ immune
cell infiltrate than control IgG-treated mice (Figure 4A). Among
these CD45+ cells, the 1H3 treatment strongly increased tumor
infiltrates of CD8 T cells and natural killer (NK) cells (Figure 4B),
two major types of antitumor immune cells. We used SPSY-
VYHQF/H-2Ld tetramer to detect CD8 T cells specific for
CT26 tumor antigen epitope AH1 (amino acids 423–431 SPSY-
VYHQF) (Huang et al., 1996). In agreement with the increased
total CD8 T cells, 1H3 treatment increased the percentage of
AH1-specific CD8 T cells (Figure 4C). In addition, we found
that the percentage of AH1-specific CD8 T cells in the blood
was reduced in 1H3-treated mice (Figure 4D), but the percent-
age of tumor-associated macrophages in the blood was not
changed by 1H3 treatment (Figure S3A). There were no signifi-
cant changes in AH1-specific CD8 T cells and tumor-associated
macrophages in spleens. These results suggest that 1H3 treat-
ment facilitated the migration of tumor-specific CD8 T cells from
the blood to tumor-bearing lungs. Recent studies identified the
coexpression of Tim-3 and PD-1 (Tim-3+PD-1+) cells as a
unique phenotype of exhausted CD8 or CD4 T cells in mela-
noma and leukemia (Fourcade et al., 2010; Goding et al.,
2013; Zhou et al., 2011). Therefore, we examined the effect of
1H3 on these two inhibitory receptors on T cells. We found
that 1H3-treated mice had significantly fewer CD4 T cells that
were Tim-3+PD-1+, Tim-3+ alone and PD-1+ alone relative to
those of control mice (Figure 4E). These results suggest that
1H3 treatment reduced the conversion of CD4 T cells from an
activated to an exhausted state. Along with these findings,
1H3 treatment enhanced CD4 T cells to produce interferon-g
(IFN-g; Figure 4F), a critical cytokine for antitumor immunity.
Perforin and granzyme B are effector molecules in CD8 T cells
and NK cells that mediate tumor cell death. We found that
1H3 treatment increased their production in CD8 T cells and
NK cells, although the difference did not reach statistical signif-
icance (Figures S3B and S3C). In the tumor microenvironment,
suppression of effector T cell function is often driven by immu-
nosuppressive cells. Therefore, we investigated the effect of
1H3 treatment on immunosuppressive cell infiltrates in tumor-
bearing lungs. We found that the treatment did not change
the percentage of Foxp3+CD4+ regulatory T cells (Tregs; Fig-
ure S3D), but it did reduce CD11b+Ly6C+ monocytic myeloid-
derived suppressor cells (MDSCs) infiltrating the tumor
(Figure 4G). The increase of CD8 T cells, NK cells, and IFN-g-
producing CD4 T cells combined with the reduction of MDSCs
in the 1H3 treatment collectively creates an environment with
a lower ratio of suppressive cells to antitumor effector cells
(Figure 4H).ors
Figure 2. Effect of Anti-B7x Monoclonal Antibodies on Tumor Growth
(A) BALB/c mice were i.v. injected with B7x/CT26, then with anti-B7x mAbs 12D11 and 1H3 or mouse IgG. After sacrifice, tumor nodules in lungs were counted.
Data were pooled from three independent experiments (n = 9 or 10).
(B) BALB/c females were injected with B7x/4T1 in the mammary fat pad. Mice were i.p. treated with mAb 1H3. Tumor volumes were measured every 2 or 3 days
after tumor injection. After mice were sacrificed, tumor weights were measured and tumor nodules on lungs were counted (n = 10). *p < 0.05.
(C) BALB/c mice were i.v. injected with CT26 cells expressing human B7x (hB7x/CT26) and then injected i.p. with mAb 1H3 or control IgG. After sacrificing the
mice, tumor nodules in the lungs were counted (n = 9). Results were pooled from two independent experiments.
(D) Several human cancers were stained with 1H3 or IgG control using immunohistochemistry. Scale bars, 50 mm.Effect of Anti-B7x Therapy on the Tumor
Microenvironment
Vascular endothelial growth factor (VEGF) from tumor cells, stro-
mal cells, and immune cells stimulates angiogenesis in the tumor
microenvironment. This angiogenesis facilitates tumor growth
andmetastasis (Roda et al., 2012; Roland et al., 2009). We found
that the VEGF concentration in tumor-bearing lungs from 1H3-
treated mice was significantly lower than that of control mice
(Figure 4I). The 1H3 treatment also lowered the concentration
of transforming growth factor b (TGF-b) in tumor-bearing lungs
(Figure 4J), one of the key cytokines responsible for suppressing
antitumor immunity (Fridlender et al., 2009).
1H3 Kills Tumor Cells through ADCC
Antibodies can eliminate virus-infected cells or tumor cells via
antibody-dependent cellular cytotoxicity (ADCC) (Clynes et al.,
2000; Isitman et al., 2012; Kohrt et al., 2012), a mechanism
requiring antibody, antigen-expressed target cells, and effector
cells expressing Fc receptors. We examined whether 1H3 was
able to kill tumor cells expressing B7x or tumor cells without ex-
pressing B7x through ADCC. We found that 1H3 induced 50%Cell Rmore target cells death compared to control IgG (Figures 5A
and S4A).
1H3 Partially Blocks B7x-Mediated T Cell Coinhibition
It has been demonstrated that B7x inhibits T cell function in the
presence of T cell receptor signaling in vitro (Prasad et al., 2003;
Sica et al., 2003; Zang et al., 2003), but the receptor expressed
on activated T cells is currently unknown. We next questioned
whether 1H3 could inhibit B7x-mediated T cell coinhibition using
a system modified from our previous studies (Zang et al., 2003).
As expected, T cells proliferated vigorously when incubated with
anti-CD3 and control immunoglobulin, with more than 73% of
T cells dividing. When T cells were incubated with anti-CD3
and B7x-Ig, significantly fewer T cells proliferated, with about
41% dividing. The presence of 1H3 in the system significantly
neutralized B7x-mediated T cell coinhibition, as 1H3 increased
T cell proliferation to >61%. Furthermore, the Fab fragment of
1H3 had a similar neutralizing effect on B7x-induced T cell coin-
hibition (Figure 5B). These results reveal that 1H3 can partially
block B7x-mediated T cell coinhibition. To assess whether 1H3
therapy depends on ADCC and/or functional neutralizationeports 9, 1089–1098, November 6, 2014 ª2014 The Authors 1093
Figure 3. Effect of Anti-B7x Therapy on Sur-
vival and Tumor Rechallenge
(A) BALB/c mice were i.v. injected with B7x/CT26
at day 0 and then injected i.p. with 1H3 or control
IgG. At day 60 postinjection, the surviving mice
were i.v. rechallenged with B7x/CT26 (n = 10). *p <
0.05; **p < 0.01.
(B) At day 120, surviving mice were sacrificed and
lung sections were used for H&E staining. Repre-
sentative lung tissues from surviving and naive
mice are shown. Scale bar, 100 mm.in vivo, we compared the therapeutic efficacies of 1H3 and its
Fab, which cannot mediate ADCC. Mice treated with Fab had
significantly fewer lung tumor nodules than did mice treated
with control IgG, but they had significantly more lung tumor nod-
ules than did mice treated with 1H3 (Figure 5C). To confirm this
effect, we validated the efficacy of 1H3 and Fab of 1H3 on the pri-
mary tumor model of B7x/4T1. 1H3 showed superior efficacy to
that of 1H3 Fab (Figure S4B). Taken together, these results sug-
gest that 1H3 inhibits tumor growth through the combination of
ADCC and functional neutralization of B7x.
DISCUSSION
Here, we solved the structure of the functional IgV domain of B7x
and developed a cancer immunotherapy targeting B7x. The B7
and CD28 families are very attractive therapeutic targets for hu-
man cancers. Compared to CTLA-4, PD-1, and PD-L1, which are
targets for current clinical trials (Brahmer et al., 2012; Topalian
et al., 2012), B7x has a very different expression pattern. In hu-
mans, CTLA-4, PD-1, and PD-L1 are not expressed on resting
T cells, but they are induced after T cell activation and expressed
on Tregs (Scandiuzzi et al., 2011). PD-1 and PD-L1 are induced
on B cells, monocytes, and other immune cells after stimulation.
By contrast, human B7x is hardly detected on immune cells even
after stimulation (Lee et al., 2012). Neither CTLA-4 nor PD-1 are
expressed on nonhematopoietic cells. PD-L1 is expressed on
some normal tissues, whereas B7x is hardly detected inmost hu-
man tissues (Choi et al., 2003). PD-L1 is expressed in some hu-
man cancers (Zang andAllison, 2007), whereas the expression of
B7x in human cancers is more extensive, including cancers of
the esophagus (Chen et al., 2011), lung (Sun et al., 2006), breast
(Tringler et al., 2005), pancreas (Awadallah et al., 2008), kidney
(Krambeck et al., 2006), gut (Jiang et al., 2010), skin (Quandt
et al., 2011), ovary (Zang et al., 2010), and prostate (Zang
et al., 2007). Therefore, the expression pattern of B7x suggests
that this target is more cancer specific.
The overall organization of the human B7x IgV domain is
similar to that of other B7 familymembers (e.g., a structural align-
ment with PD-L1 is shown in Figure 1C). In addition to the
secondary structure topology, conserved features include the di-
sulfide bond connecting strands B and F (formed by Cys56 and
Cys130) and the tryptophan residue (Trp71) at the domain core.
The receptor-binding interface described for other B7 family
members is located on the front-sheet surface of their IgV do-
mains (La´za´r-Molna´r et al., 2008; Schwartz et al., 2001; Stamper1094 Cell Reports 9, 1089–1098, November 6, 2014 ª2014 The Authet al., 2001). Thus, it is likely that B7x engages its receptor on the
equivalent surface. Furthermore, our observation of a large
branched glycan of the back sheet of the B7x-IgV (linked to
Asn112) would suggest that the back-sheet surface is unlikely
to participate in receptor recognition. A glycosylation site at an
equivalent position has been previously reported for the murine
B7-H3 ectodomain (Vigdorovich et al., 2013).
We demonstrated that mAbs against B7x achieved significant
therapeutic efficacy in mouse cancer models. A new study also
demonstrates that the anti-B7x single-chain fragments variable
(scFv) can delay OVCAR5 line growth in NSG mice (Dangaj
et al., 2013). We and other groups have previously shown that
activated T cells express an unidentified receptor for B7x (Pra-
sad et al., 2003; Sica et al., 2003; Zang et al., 2003), and our
recent work reveals that MDSCs also have a receptor for B7x
(Abadi et al., 2013). These results suggest that the expression
of the B7x receptors is broader than previously thought. Due to
the lack of the identity of B7x receptors, we developed an in vivo
functional screen for anti-B7x mAbs. We found that the expres-
sion of B7x on CT26 tumor cells significantly promoted tumor
progression in vivo, which mirrored clinical observations, and
was used to validate therapeutic mAbs. 1H3 and 12D11 were
found to reduce more than 60% of tumor nodules in lungs,
with development of a strong immunologic memory in the case
of 1H3. Similar results were obtained with the 4T1 tumor model.
Characterization of 1H3’s binding properties showed that in
addition to recognizing murine B7x, it also bound strongly to
the IgV domain of human B7x and was able to significantly inhibit
tumor nodule formation of human B7x-expressing CT26 in lungs.
These results suggest that humanized 1H3 may prove useful in
the treatment of human cancers. To advance this strategy, we
mapped the epitopes recognized by 1H3 on human B7x using
a series of mutants whose design was guided by the structure
of B7x-IgV. The clustering of the antibody-blocking mutants to
the ‘‘top’’ of the molecule, in particular, residues Ile62 and
Lys63 in the BC loop of the back sheet and residue Ser135 in
the FG loop of the front sheet, defines the minimal footprint for
the B7x:1H3 binding interface. The combination of 1H3 func-
tional blocking data and the mutagenesis data suggests that
the binding surface for the physiologically relevant B7x receptor
partially overlaps with this surface. Our results are consistent
with observations that IgV domains predominately interact with
other IgV domains via strands and a loop on their front sheets
like is seen in the interactions between CTLA-4 and PD-1 and
their ligands (Figures S5A–S5D).ors
Figure 4. Anti-B7x Therapy Alters the Intratumor Balance of Antitumor Effector Immune Cells and Immunosuppressive Cells
(A–G) BALB/cmice were i.v. injected with B7x/CT26 and then treated with 1H3 or control mouse IgG. At day 17, single-cell suspensions from tumor-bearing lungs
were analyzed by FACS for the percentage of infiltrated CD45+ cells (A), the percentage of CD8 T cells and NK cells (B), the percentage of tumor antigen AH1
(SPSYVYHQF)-specific CD8 T cells (C), the percentage of CD4 T cells that were Tim-3+PD-1+, Tim-3+ alone and PD-1+ alone (E), and CD11b+Ly6C+ monocytic
myeloid-derived suppressor cells (G). At day 17, single-cell suspensions from blood were analyzed by FACS for the percentage of tumor antigen AH1-specific
CD8+ T cells were measured (D). Cell suspensions from tumor-bearing lungs were stimulated with 13 cell stimulation cocktail for 5 hr and stained with antibodies
to CD3, CD4 and IFN-g or isotype controls (F). Results are pooled from three independent experiments; *p < 0.05, **p < 0.01. Result in (D) is representative of data
from two independent experiments.
(H) The ratios of Treg (Foxp3+CD4+) and MDSCs to CD8 T cells, CD4 T cells, and NK cells. These results are pooled from three independent experiments; *p <
0.05, **p < 0.01, ***p < 0.001.
(I) Total amount of VEGF from tumor-bearing lungs was measured using ELISA. **p < 0.01.
(J) Total amount of TGF-b from tumor-bearing lungs was measured using ELISA. Each group contained five mice. *p < 0.05.It is surprising that 1H3 and 12D11 recognized similar epitopes
in human B7x, because 12D11 showed no in vivo suppressive
effect on human B7x-expressing CT26 cells. However, even
though the difference was minor, 1H3 and 12D11 had at least
one difference. Ile62’s position in the IgV domain of human
B7x seemed to play a significant role in the binding of B7x and
anti-B7x mAbs. These results highlight the importance of our
in vivo screening system to find therapeutic mAbs against B7x.
The studies presented here suggest that the principal mecha-
nisms of the anti-B7x mAb in dampening tumor progression are
the neutralization of the B7x-mediated coinhibition of T cells and
the ADCC-mediated direct killing of tumor cells. We demon-
strated that 1H3 killed B7x-expressing tumor cells in a dose-
dependent manner and that both 1H3 and its Fab fragment
partially recovered T cell proliferation suppressed by B7x-Ig
fusion protein. In line with these results, the Fab treatment signif-
icantly reduced lung tumor nodules, but its therapeutic efficacy
was not as great as full 1H3 mAb treatment. These results sug-Cell Rgest that both neutralization and ADCC may take place in vivo
during the 1H3 treatment. The 1H3 treatment strongly increased
the infiltration of major types of antitumor immune cells such as
CD8 T cells including tumor antigen-specific CD8 T cells, NK
cells, and IFN-g-producing CD4 T cells. On the other hand, the
treatment markedly reduced infiltration of immunosuppressive
MDSCs. As a consequence, the treatment shifted the tumor
microenvironment to a favorable antitumor state with a signifi-
cantly higher ratio of effector immune cells to the suppressive
MDSCs and Tregs. Correspondingly, we found less VEGF and
TGF-b in the tumor microenvironment after 1H3 treatment.
Therapies with mAbs against CTLA-4 and PD-1 target T cell
coinhibitory receptors, whereas therapies with mAbs against
PD-L1 and B7x target T cell coinhibitory ligands. The encour-
aging safety profile and antitumor activity from an anti-PD-L1
clinical trial (Brahmer et al., 2012), together with preliminary
data froman anti-PD-1 trial that have suggested a correlation be-
tween tumor membrane PD-L1 expression and clinical responseeports 9, 1089–1098, November 6, 2014 ª2014 The Authors 1095
Figure 5. Antitumor Mechanisms of 1H3
Treatment
(A) mAbs against B7x killed CT26 tumor cells ex-
pressing B7x through antibody-dependent cellular
cytotoxicity in vitro. Data are representative of two
independent experiments in triplicates and shown
as mean ± SE. **p < 0.01; ****p < 0.0001.
(B) 1H3 partially neutralized B7x-mediated T cell
coinhibition. CFSE-labeled T cells were incubated
for four days with plate-bound anti-CD3 in the
presence of control Ig, B7x-Ig and IgG (2 mg/ml),
B7x-Ig and 1H3 (2 mg/ml), or B7x-Ig and 1H3 Fab
(4 mg/ml). Representative FACS plots show CFSE
dilution among live stimulated cells (solid line) compared to unstimulated control T cells (shaded area). Data are representative of two independent experiments.
(C) Comparison of therapeutic efficacies between 1H3 and its Fab. Data were pooled from two independent experiments (n = 9 or 10). *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 0.0001.to anti-PD-1 antibodies (Topalian et al., 2012), highlight the
emerging significance of targeting coinhibitory B7 ligands.
Further studies with humanized anti-B7x antibodies, either as
monotherapy or in synergism with traditional therapies, should
be pursued for the treatment of human cancers.
EXPERIMENTAL PROCEDURES
Protein Crystallization and Structure Determination
Purified human B7x IgV protein was concentrated to 10 mg/ml in HBS-E
(10 mM HEPES [pH 7], 150 mM NaCl, 1 mM EDTA) and used to determine
the initial crystallization conditions. Diffraction-quality crystals were obtained
in 200 mM tripotassium citrate, 2.2 M ammonium sulfate, soaked in the well
solution supplemented with 5-amino-2,4,6 triiodoisophthalic acid monohy-
drate (I3C) (Hampton Research) as a phasing reagent and 400 mM (final vol-
ume) lithium sulfate and flash-cooled in liquid nitrogen. Data sets at 1.075 A˚
and 1.54 A˚ wavelength were collected at the National Synchrotron Light
Source beamline X29 (Upton, NY). Data were integrated using the iMosflm
(Battye et al., 2011) with subsequent processing using the programs within
the CCP4 software package (Winn et al., 2011). Single-wavelength anomalous
dispersion (SAD) phasing was carried out using the anomalous iodine (I3C)
signal from a data set collected at 1.54 A˚, and the initial electron density
maps were obtained using SHELXC/D/E (Sheldrick, 2008) and HKL2MAP.
Following initial model building using ARP/wARP (Langer et al., 2008), the
model was refined using REFMAC5 (Murshudov et al., 1997) with further
manual building using Coot (Emsley et al., 2010).
Animals and Human Tissue Slides
BALB/c mice were purchased from the National Cancer Institute and The
Jackson Laboratory. All mice were housed in a specific-pathogen-free facility.
Human tumor tissue sections were obtained from IMEGENEX. All protocols
were reviewed and approved by the Albert Einstein College of Medicine Insti-
tutional Animal Care and Use Committee and Institutional Review Board.
Monoclonal Antibodies against B7x andGeneration of Fab Fragment
Hybridoma cells from 37G9, 12D11, 1H3, and 15D12 clones were maintained
in serum-free RPMI-1640 media (Wei et al., 2011). mAbs were purified on a
Protein G column (Thermo Scientific). Fractions of eluted mAbs were
measured and pooled for buffer exchange to PBS via dialysis. Fab fragment
preparation was performed based on the manufacturer’s protocol (Thermo
Scientific).
Cell Lines and Tumors
CT26 and B7x/CT26 were cultured in RPMI-1640 containing 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine,
1% nonessential amino acids, and 1 mM sodium pyruvate. 4T1 and B7x/4T1
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10%FBS and 0.4 U/ml insulin as described previously (Abadi et al., 2013).1096 Cell Reports 9, 1089–1098, November 6, 2014 ª2014 The AuthThe 8- to 10-week-old mice were i.v. injected with 105 cells in 0.2 ml DMEM.
For survival studies of CT26 and B7x/CT26, 105 B7x/CT26 cells were i.v. in-
jected into mice and survival rate was examined. For survival studies of 1H3
treatment, 104 B7x/CT26 cells were i.v. injected into mice, and the same
numbers of B7x/CT26 cells were injected for rechallenge. For the primary
tumor experiment, 105 B7x/4T1 cells were injected subcutaneously into the
mammary fat pad of female mice. Tumor nodules on lungs were measures
as previously described (Abadi et al., 2013).
Anti-B7x Immunotherapy
A total of 200 mg of mAbs against B7x, 1H3 Fab, or normal mouse IgGwere i.p.
injected at days 1, 3, 7, 11, and 14. Eachmouse received a total of 1mg of anti-
body or Fab during B7x/CT26 experiments. At day 17, mice were sacrificed for
counting tumor nodules in lungs. For hB7x/CT26 experiments, 200 mg of mAbs
against B7x (1H3 and 12D11) or normal mouse IgG was i.p. injected at days 1,
2, 3, 5, 7, 9, 11, 13, and 15. Each mouse received a total of 1.8 mg antibody. At
day 17, mice were sacrificed for counting tumor nodules in lungs. For the B7x/
4T1 primary tumor model, 1 week after tumor injection, mice were grouped
based on their tumor volume. A total of 300 mg of mAbs was i.p. injected at
days 8, 11, 13, 15, and 18. Tumor volumewasmeasured every 2 or 3 days after
7 days. At day 20, mice were sacrificed, breast tumors were excised and
weighed, and tumor nodules on lungs were counted.
Human B7x Mutagenesis and Epitope Mapping
Ectodomain of hB7x (Gly21-Ala208) was cloned into a type I secretion ligation
independent cloning vector we designed in house. Cloning into this vector
fuses the target ectodomain to a nonnative transmembrane domain (TM
domain from murine PD-L1) followed by the mCherry protein (as a cytosolic
expression proxy). We have successfully used this vector to study expression,
localization, and activity of several other members of the IgG superfamily. The
wild-type hB7x type I secretion construct was transfected into human embry-
onic kidney 293S (HEK293S) cells. Cell-surface expression of B7x was
confirmed by fluorescence-activated cell sorting (FACS) analysis using the
B7x-specific mAb 1H3. Residues for site-directed mutagenesis were initially
selected on the basis of our crystal structure of the hB7x-IgV domain to identify
surface-exposed residues within the IgV domain. Surface-exposed residues
clearly involved in a salt bridge were omitted from the set of targeted residues.
Mutagenesis was performed using a standard PCR method using high-fidelity
KOD polymerase. All of the successful mutants were sequence-verified and
individually transfected into HEK293S cells using 24-well suspension plates.
Two days posttransfection, the cells were counted and diluted to 1 3 106
cells/ml using 13 PBS with 2% BSA. A total of 0.23 106 cells were incubated
with 2 mg of the 1H3 mAb for 1 hr at 4C. Cells were subsequently pelleted by
centrifugation at 5003 g and washed with PBS for a total of three times. Goat
anti-mouse DyLight 488 secondary antibody (2 mg) was added to the cells, and
they were incubated at 4C for 45 min. Cells were washed, and antibody bind-
ing was assessed by FACS analysis on a BD Aria III. Flow cytometry data were
gated for all mCherry-positive events (hB7x expression) and then subgated for
anti-B7x binding (488 channel). To consider slight variation in total expressionors
of eachmutant, the number of antibody-bound events was divided by the total
number of mCherry-positive events. The experiment was performed in
duplicate.
Statistics
Statistical analysis was performed with Prism software (GraphPad) using the
unpaired Student’s t test or the log-rank test (Mantel-Cox) for the survival
study. p values < 0.05 were considered statistically significant.
Other detailed experimental procedures can be found in the Supplemental
Experimental Procedures.
ACCESSION NUMBERS
Final coordinates and structure factors were deposited in Protein Data Bank
and are available under accession number 4GOS.
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